The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern.

Viral adaptability and survival arise due to the presence of quasispecies populations that are able to escape the immune response or produce drug-resistant variants. However, the presence of H5N1 virus with natural mutations acquired without any drug selection pressure poses a great threat. Cloacal samples collected from the 2004-2005 epidemics in Thailand from Asian open-billed storks revealed one major and several minor quasispecies populations with mutations on the oseltamivir (OTV)-binding site of the neuraminidase gene (NA) without prior exposure to a drug. Therefore, this study investigated the binding between the NA-containing novel mutations and OTV drug using molecular dynamic simulations and plaque inhibition assay. The results revealed that the mutant populations, S236F mutant, S236F/C278Y mutant, A250V/V266A/P271H/G285S mutant and C278Y mutant, had a lower binding affinity with OTV as compared with the WT virus due to rearrangement of amino acid residues and increased flexibility in the 150-loop. This result was further emphasized through the IC50 values obtained for the major population and WT virus, 104.74 nM and 18.30 nM, respectively. Taken together, these data suggest that H5N1 viruses isolated from wild birds have already acquired OTV-resistant point mutations without any exposure to a drug.

[1]  Daniel J. Sindhikara,et al.  A 3D‐RISM/RISM study of the oseltamivir binding efficiency with the wild‐type and resistance‐associated mutant forms of the viral influenza B neuraminidase , 2016, Protein science : a publication of the Protein Society.

[2]  J. Correa-Basurto,et al.  Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase , 2015, Journal of Molecular Modeling.

[3]  M. Soliman,et al.  Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses , 2015, Drug design, development and therapy.

[4]  J. Järhult,et al.  Influenza A(H7N9) Virus Acquires Resistance-Related Neuraminidase I222T Substitution When Infected Mallards Are Exposed to Low Levels of Oseltamivir in Water , 2015, Antimicrobial Agents and Chemotherapy.

[5]  J. Nguyen-Van-Tam,et al.  Neuraminidase inhibitors: who, when, where? , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  J. McKimm-Breschkin,et al.  Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. , 2015, Antiviral research.

[7]  Julian E. Fuchs,et al.  Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity , 2013, Journal of biomolecular structure & dynamics.

[8]  Kuk Jin Park,et al.  Profiling and Characterization of Influenza Virus N1 Strains Potentially Resistant to Multiple Neuraminidase Inhibitors , 2014, Journal of Virology.

[9]  A. Nitsch-Osuch,et al.  Influenza viruses resistant to neuraminidase inhibitors. , 2014, Acta biochimica Polonica.

[10]  K. Ramanathan,et al.  Insight into the Oseltamivir Resistance R292K Mutation in H5N1 Influenza Virus: A Molecular Docking and Molecular Dynamics Approach , 2013, Cell Biochemistry and Biophysics.

[11]  Hiroshi Ohrui,et al.  Functional and Structural Analysis of Influenza Virus Neuraminidase N3 Offers Further Insight into the Mechanisms of Oseltamivir Resistance , 2013, Journal of Virology.

[12]  Yuguang Mu,et al.  Plasticity of 150-Loop in Influenza Neuraminidase Explored by Hamiltonian Replica Exchange Molecular Dynamics Simulations , 2013, PloS one.

[13]  J. McKimm-Breschkin,et al.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance , 2013, Influenza and other respiratory viruses.

[14]  J. Correa-Basurto,et al.  Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1. , 2013, Biopolymers.

[15]  P. Walker,et al.  Outbreaks of H5N1 in poultry in Thailand: the relative role of poultry production types in sustaining transmission and the impact of active surveillance in control , 2012, Journal of The Royal Society Interface.

[16]  Parimal Kar,et al.  Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase. , 2012, The journal of physical chemistry. B.

[17]  J. Nicholls,et al.  Highly Pathogenic Influenza A(H5N1) Virus Survival in Complex Artificial Aquatic Biotopes , 2012, PloS one.

[18]  R. Webster,et al.  Fitness of neuraminidase inhibitor-resistant influenza A viruses. , 2011, Current opinion in virology.

[19]  J. Lynch,et al.  Influenza: epidemiology, clinical features, therapy, and prevention. , 2011, Seminars in respiratory and critical care medicine.

[20]  Robert V. Swift,et al.  Mechanism of 150-cavity formation in influenza neuraminidase , 2011, Nature communications.

[21]  G. Gao,et al.  Influenza A Virus N5 Neuraminidase Has an Extended 150-Cavity , 2011, Journal of Virology.

[22]  M. Fukuda,et al.  Intra-host diversities of the receptor-binding domain of stork faeces-derived avian H5N1 viruses and its significance as predicted by molecular dynamic simulation , 2011, The Journal of general virology.

[23]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[24]  John Z H Zhang,et al.  Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase. , 2010, The journal of physical chemistry. B.

[25]  Klaus Schulten,et al.  Molecular Dynamics Simulations Suggest that Electrostatic Funnel Directs Binding of Tamiflu to Influenza N1 Neuraminidases , 2010, PLoS Comput. Biol..

[26]  R. Webster,et al.  Antiviral Susceptibility of Avian and Swine Influenza Virus of the N1 Neuraminidase Subtype , 2010, Journal of Virology.

[27]  David Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[28]  P. Daszak,et al.  Ecology of avian influenza viruses in a changing world , 2010, Annals of the New York Academy of Sciences.

[29]  R. Webster,et al.  Effect of Neuraminidase Inhibitor–Resistant Mutations on Pathogenicity of Clade 2.2 A/Turkey/15/06 (H5N1) Influenza Virus in Ferrets , 2010, PLoS pathogens.

[30]  Hiroaki Tanaka,et al.  Oseltamivir Carboxylate, the Active Metabolite of Oseltamivir Phosphate (Tamiflu), Detected in Sewage Discharge and River Water in Japan , 2009, Environmental health perspectives.

[31]  Gabriele Neumann,et al.  H5N1 influenza viruses: outbreaks and biological properties , 2010, Cell Research.

[32]  Thanyada Rungrotmongkol,et al.  How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? , 2009, Biophysical chemistry.

[33]  Thanyada Rungrotmongkol,et al.  Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues , 2009, J. Chem. Inf. Model..

[34]  Thanyada Rungrotmongkol,et al.  Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. , 2009, Biochemical and biophysical research communications.

[35]  A. Kelso,et al.  Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation , 2009, Journal of Virology.

[36]  J. Fick,et al.  Detection of the Antiviral Drug Oseltamivir in Aquatic Environments , 2009, PloS one.

[37]  J. Andrew McCammon,et al.  Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations , 2009, Journal of the American Chemical Society.

[38]  H. Hsieh,et al.  Aurintricarboxylic acid inhibits influenza virus neuraminidase , 2008, Antiviral Research.

[39]  Thanyada Rungrotmongkol,et al.  Understanding of known drug‐target interactions in the catalytic pocket of neuraminidase subtype N1 , 2008, Proteins.

[40]  B. Lina,et al.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[41]  B. Lina,et al.  Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[42]  I. Barr,et al.  Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues. , 2007, Antiviral research.

[43]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors , 2007, Nature Reviews Drug Discovery.

[44]  Mats Tysklind,et al.  Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A Virus , 2007, PloS one.

[45]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo , 2007, Journal of Virology.

[46]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.

[47]  Jung-Hsin Lin,et al.  Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. , 2007, Journal of the American Chemical Society.

[48]  I. Barr,et al.  Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. , 2007, Antiviral research.

[49]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.

[50]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[51]  R. Webster,et al.  Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza Viruses , 2006, Journal of Virology.

[52]  F. Agou,et al.  Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir , 2006, Antimicrobial Agents and Chemotherapy.

[53]  R. Webster,et al.  Domestic Ducks and H5N1 Influenza Epidemic, Thailand , 2006, Emerging infectious diseases.

[54]  F. Hayden,et al.  Antiviral resistance in influenza viruses--implications for management and pandemic response. , 2006, The New England journal of medicine.

[55]  D. Lewis,et al.  Avian flu to human influenza. , 2006, Annual review of medicine.

[56]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[57]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[58]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.

[59]  Yoshihiro Kawaoka,et al.  Influenza: lessons from past pandemics, warnings from current incidents , 2005, Nature Reviews Microbiology.

[60]  P. Palese,et al.  Influenza: old and new threats , 2004, Nature Medicine.

[61]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[62]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  N. Cox,et al.  Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. , 1999, Virology.

[64]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .

[65]  P. Colman.  Influenza virus neuraminidase: Structure, antibodies, and inhibitors , 1994, Protein science : a publication of the Protein Society.

[66]  T. Darden,et al.  The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .

[67]  R. Krug,et al.  The Influenza Viruses , 2011, The Viruses.

[68]  W. L. Jorgensen,et al.  Computer Simulations of Organic Reactions in Solution a , 1986, Annals of the New York Academy of Sciences.

[69]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[70]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[71]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .